Istradefylline Pill
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Parkinson Disease
Conditions
Parkinson Disease, Tremor
Trial Timeline
Jan 20, 2023 → Feb 21, 2025
NCT ID
NCT05885360About Istradefylline Pill
Istradefylline Pill is a approved stage product being developed by Kyowa Kirin for Parkinson Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05885360. Target conditions include Parkinson Disease, Tremor.
What happened to similar drugs?
20 of 20 similar drugs in Parkinson Disease were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05885360 | Approved | Completed |
Competing Products
20 competing products in Parkinson Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 36 |
| UB-312 + Placebo | Vaxxinity | Phase 1 | 19 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 22 |
| LY4006896 + Placebo | Eli Lilly | Phase 1 | 36 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 17 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 35 |
| Mirabegron + Placebo | Astellas Pharma | Approved | 43 |
| E2007 | Eisai | Phase 3 | 32 |
| ARICEPT | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Phase 3 | 32 |
| GPI 1485 | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 3 | 40 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 40 |
| Equfina 50 mg | Eisai | Pre-clinical | 26 |
| Equfina | Eisai | Pre-clinical | 26 |
| perampanel + placebo | Eisai | Phase 2 | 27 |
| Lemborexant + placebo | Eisai | Approved | 50 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 32 |
| Safinamide Mesilate | Eisai | Approved | 43 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 35 |